For instance, an LXR inverse agonist is effective against various types of cancer without obvious side effects [52]; therefore, it should be determined whether the LXRβ-targeting treatment could be a therapeutic option in the "CLDN4-high/LXRβ-high" TNBC cases. Here, CLDN4 is linked to cancer.